IncFact
Company Profiles: Revenue, Growth, Competition

SAREPTA THERAPEUTICS Revenue, Growth & Competitor Profile

DBA AVI BIOPHARMA, INC.
DBA SAREPTA
Last updated:

Company Awards

 
Public Company
public company
Fast Growing
Fastest Growing
Big Fish
Big Fish
Brain Power (IP)
Patent/Trademark IP
 

Company Profile & Annual Report for Sarepta Therapeutics

Access the complete profile.

Sarepta Therapeutics Fast Facts

Revenue$100 - $500 million    See Exact Annual Revenue
Employees100 - 500Exact Company Size
Primary Industry325411 Medicinal & Botanical Manufacturing
Additional NAICS Codes32541
325412 Pharmaceutical Preparation Manufacturing
5417 Scientific Research & Development Services
541711 Research & Development in Biotechnology
541714
Address215 1st St Ste 415
Cambridge, MA 02142

www.sarepta.com


Sarepta Therapeutics's annual revenues are $100-$500 million (see exact revenue data) and has 100-500 employees. It is classified as operating in the Medicinal & Botanical Manufacturing industry.


Sarepta Therapeutics's Annual Report & Profile shows critical firmographic facts:
  • What is the company's size? (Annual sales and employees)
  • What industry is the company in?

Sarepta Therapeutics is a publicly traded company on NMS using the ticker symbol SRPT. Detailed information on company financials and operating reports can be found here: NMS: SRPT



Sarepta Therapeutics Annual Revenue and Growth Rate

Sarepta Therapeutics Revenue Est.
($ Million)
Growth Rate (%)# Employees
2019 Details in Premium Report
2018
2017
2016
2015
2014


1-Year Growth Rate:
3-Year Growth Rate (CAGR):
Premium Report

Note: Sarepta Therapeutics's revenues are gauged from an analysis of company filings.



Investor Activity

Sarepta Therapeutics has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.

Date Investors Percent Raised Target Size
February 28, 2020 1 100%$400 MM
Complete list of funding rounds and total amounts in the Company Report




Trademark Applications

Trademark applications show the products and services that Sarepta Therapeutics is developing and marketing. Sarepta Therapeutics's new tradmarks suggest it is investing in R&D and marketing, while expanding into new products or markets. Trademarks may include brand names, product names, logos and slogans.

Trademark Date
MYOSTRADA
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
04/30/2020
ELEVIDYS
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
04/24/2020
DYSTAVIO
Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapies for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases
04/24/2020

See all trademarks and details in the Full Report.


Recession Risk

Determine whether Sarepta Therapeutics grew or shrank during the last recession. This is useful in estimating the financial strength and credit risk of the company. Compare how recession-proof Sarepta Therapeutics is relative to the industry overall. While a new recession may strike a particular industry, measuring the industry and company's robustness during the last recession estimates its ability to weather future recessions.



U.S. Industry Overview & Market Statistics:
Medicinal & Botanical Manufacturing

Publisher: AnythingResearch

  • Market Size
  • Growth Rate
  • 5-Year Market Forecast
  • Average Company Size & Growth
  • Salary & Compensation Benchmarks



Market Share of Sarepta Therapeutics's Largest Competitors

A competitive analysis shows these companies are in the same general field as Sarepta Therapeutics, even though they may not compete head-to-head. These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines. The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies. Competitive advantage comes from offering better pricing or superior products/service.

Company HeadquartersRevenue ($ MM)
PANACEA BIOMATXResearch Triangle Park, NC100 
TMUNITY THERAPEUTICSPhiladelphia, PA60 




Nearby Competitors

These companies are similar in business line and location to Sarepta Therapeutics. While some companies compete with neighboring businesses for customers, other companies may compete to attract skilled employees.

Company HeadquartersRevenue ($ MM)
ABCAMCambridge, MA100 
SAREPTA THERAPEUTICSCambridge, MA100 
BRAINTREE LABORATORIESBraintree, MA46 
FOGHORN THERAPEUTICSCambridge, MA36 
RUBIUS THERAPEUTICSCambridge, MA26 
SERVIER PHARMACEUTICALSBoston, MA20 




Future Competition: Sarepta Therapeutics's Fastest Growing Competitors

These companies are in the same general field as Sarepta Therapeutics and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.

CompanyRevenue ($ MM)
Sarepta Therapeutics Competitors